title: Three different KRAS statuses in three synchronous colorectal cancers.
abstract: Treatments with monoclonal antibodies targeting the epidermal growth factor receptors (EGFR) have improved the prognosis of metastatic colorectal cancer (CRC). Mutated KRAS status is predictive of resistance to anti-EGFR agents and allows the selection of KRAS wild-type patients who may benefit from these targeted therapies. We report an original case of metastatic CRC including three synchronous primary tumors with three different KRAS statuses. We discuss the possible therapeutic impact of this clinical case and the role of multiple samplings for KRAS status determination.
authors.affiliation: Department of Medical Oncology, Institut Curie, Université Paris Descartes, 26 rue d'Ulm, 75248, Paris Cedex 05, France.
authors.forename: L
authors.initials: L
authors.lastname: Jolissaint
authors.forename: W
authors.initials: W
authors.lastname: Cacheux
authors.forename: P
authors.initials: P
authors.lastname: Mariani
authors.forename: C
authors.initials: C
authors.lastname: Le Tourneau
authors.forename: A
authors.initials: A
authors.lastname: Lièvre
authors.forename: E
authors.initials: E
authors.lastname: Lappartient
authors.forename: A
authors.initials: A
authors.lastname: Margogne
authors.forename: F
authors.initials: F
authors.lastname: Farkhondeh
authors.forename: P
authors.initials: P
authors.lastname: de Cremoux
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009378:Neoplasms, Multiple Primary / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins